T. Rowe Price Investment Management
HAE icon

T. Rowe Price Investment Management’s Haemonetics HAE Stock Holding History

T. Rowe Price Investment Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.7M Sell
597,155
-346,030
-37% -$22.5M 0.02% 403
2025
Q4 		$75.6M Sell
943,185
-67,772
-7% -$4.55M 0.05% 294
2025
Q3 		$49.3M Sell
1,010,957
-583,910
-37% -$36.1M 0.03% 392
2025
Q2 		$119M Sell
1,594,867
-600,702
-27% -$39.8M 0.08% 248
2025
Q1 		$140M Sell
2,195,569
-358,245
-14% -$24.4M 0.09% 222
2024
Q4 		$199M Sell
2,553,814
-296,823
-10% -$23.8M 0.12% 179
2024
Q3 		$229M Buy
2,850,637
+1,207,696
+74% +$97.6M 0.14% 168
2024
Q2 		$136M Buy
1,642,941
+424,730
+35% +$37.4M 0.09% 233
2024
Q1 		$104M Buy
1,218,211
+125,912
+12% +$9.88M 0.06% 287
2023
Q4 		$93.4M Buy
1,092,299
+245,382
+29% +$21.2M 0.06% 285
2023
Q3 		$75.9M Buy
+846,917
New +$75.6M 0.05% 297

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management's HAE Position: Q1 2026 in Review

T. Rowe Price Investment Management reduced its Haemonetics (HAE) stake by 37% in Q1 2026, selling an estimated $22.5M and leaving 597,155 shares worth $33.7M. The position accounts for 0.02% of the portfolio, ranked #403.

T. Rowe Price Investment Management first reported a position in HAE in Q3 2023 and has held it in 11 quarters since. The position peaked at $229M in Q3 2024. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • T. Rowe Price Investment Management held 597,155 shares of Haemonetics worth $33.7M as of Q1 2026.
  • T. Rowe Price Investment Management sold 346,030 Haemonetics shares in Q1 2026, an estimated $22.5M.
  • Haemonetics made up 0.02% of T. Rowe Price Investment Management's portfolio in Q1 2026, its #403 holding.
  • T. Rowe Price Investment Management first reported a position in Haemonetics in Q3 2023 and has held it in 11 quarters since.
  • T. Rowe Price Investment Management's Haemonetics position peaked at $229M in Q3 2024.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on T. Rowe Price Investment Management's 13F filing for Q1 2026, filed 15 May 2026.